Company: RPTX
Filing Date: 2025-12-03
Form Type: PREM14A
Source: 0001193125-25-306948
Chunk: 229

Company: Repare Therapeutics Inc.
Filing Date: 2025-12-03
Form: PREM14A
Chunk 229
---
 shall have the meanings ascribed to them 
 in this Agreement;                                                                                              |

| (k) | time is of the essence in the performance of the Parties’ respective obligations; and |

| (l) | unless otherwise specified, time periods within or following which any payment is to be made or act is to be                                                                                                                                    
 done, shall be calculated by excluding the day on which the period commences and including the day on which the period ends and by extending the period to the next Business Day following if the last day of the period is not a Business Day. |

A-17

| 1.3 | Knowledge |

Where any representation or warranty is expressly qualified by reference to knowledge of the Company, it is deemed to refer to the knowledge of Steve Forte, President, CEO and CFO, Michael Zinda, EVP, Chief Scientific Officer, Daniel Bélanger, EVP, Human Resources, Joseph O’Connell, EVP, Clinical Development & Medical Affairs, and Sandra Alves, Senior Vice President and Chief Accounting Officer, after due inquiry, but, in each case, without the requirement to make any inquiries of any Governmental Entity or persons who are not directors, officers, employees or Representatives of the Company or to perform any search of any public registry office or system (and, without limiting the foregoing, each such individual will be deemed to have “knowledge” of a particular fact or other matter if (a) that individual is actually aware of that fact or matter; or (b) that fact or matter comes to the attention of that individual under circumstances in which a reasonable person would take cognizance of it).

| 1.4 | Currency |

Unless otherwise indicated, all dollar amounts referred to in this Agreement are expressed in lawful money of the United States.

| 1.5 | Accounting Principles |

Any reference in this Agreement to generally accepted accounting principles or “GAAP” refers to accounting principles which have been established in accordance with GAAP, applied on a consistent basis, and which are applicable in the circumstances as of the date in question. Accounting principles shall be applied on a “consistent basis” when the accounting principles applied in a current period are comparable in all material respects to those accounting principles applied in a preceding period.

| 1.6 | Disclosure in Writing |

| (a) | Reference to disclosure in writing herein shall, in the case of the Company, be limited to the disclosures made                                                                                                                                           
 by the Company in this Agreement (including the Schedules hereto) and the Disclosure Letter. The Parties